Compelling industrial AI use cases, strong execution and AI-driven demand fuel global growth

LONDON, July 23, 2025 /PRNewswire/ — IFS, the leading provider of enterprise cloud and Industrial AI software, today announced record-setting H1 2025 results. The company is rewriting the rules of enterprise software with Industrial AI that acts, learns, and delivers. In H1, IFS outpaced legacy enterprise vendors, driving double-digit growth across all key performance metrics, further validating the strength of IFS’s strategy, the scalability of its model, and accelerating momentum as the category leader in Industrial AI.

IFS H1 2025 Key Financial Results:

• Annual Recurring Revenue (ARR): +30% YoY
• Cloud Revenue: +37% YoY
• Recurring Revenue: +24% YoY (now 82% of total revenue)

Unlike traditional, legacy software vendors, IFS is purpose-built for the operational core of industrial businesses, powering the real-world systems that keep the world running. Average customer deal size from new customers continued to grow significantly in the first half of the year, with 130 leading industrial brands choosing to future-proof their growth with IFS in H1, including: Arcelor Mittal, Callaway, Collins Aerospace, Hitachi Energy, Japan Airlines, TotalEnergies.

In addition to continued organic growth, IFS extended its Industrial AI lead with the acquisition of TheLoops, launching the first agentic AI workforce for complex industries. Complementing this, the launch of Nexus Black, IFS’s AI innovation accelerator, is already delivering bespoke, scalable solutions that traditional platforms cannot match.

Together, Nexus Black and TheLoops mark a new era for enterprise software, where self-learning AI agents operate in real time inside customer environments, reducing manual effort and accelerating decisions from edge to boardroom.

“Our phenomenal growth proves customers are done with AI theory. They want AI that solves real problems, at scale, and are placing their trust in IFS to lead them through the Industrial AI revolution,” said Mark Moffat, CEO of IFS. “The connection between our performance and AI innovation is unmistakable. As demand intensifies, IFS stands apart, thanks to our domain depth, contextual intelligence, and unwavering focus on industry.”

Matthias Heiden, CFO of IFS commented: “Our fiscal performance reflects the fast-growth, differentiated Industrial AI leader that IFS has become, with a disciplined financial model rooted in recurring revenue, resilient operations, and scale-ready agility. These same principles are built into our solutions to empower our customers to drive long-term value. With this strong foundation, we’re not just growing, we’re redefining what’s possible for industrial enterprises.”

Demand for AI-powered solutions from prior acquisitions – Copperleaf, Poka, Ultimo, P2 and EmpowerMX – remains strong and continues to contribute meaningfully to IFS’s growth. IFS’s thriving global network of strategic partners also played a key role in enabling continued scaling and deal size growth.

H1 Highlights: 

AI and Innovation

• Launched Nexus Black: bespoke accelerator for industrial-grade scalability and security
• Acquired TheLoops: first agentic AI workforce for mission-critical industries
• Released IFS Cloud 25R1: made 200+ AI-driven capabilities

Market Momentum and Recognition

• EUR 15 billion valuation amid soaring Industrial AI demand
• Only company named Customers’ Choice in the 2025 Gartner Peer Insights Voice of the Customer for EAM report
• IFS ranked #1 for EAM for fourth consecutive year, Gartner Market Share: Enterprise Software, Worldwide, 2024 report
• Named a Leader in two IDC MarketScape 2024-2025 Vendor Assessments in two IDC MarketScape 2024-2025 Vendor Assessments
• IFS appointed Advisor to UK Parliamentary Group on AI

IFS Press Contacts:
EUROPE / MEA / APJ: Adam Gillbe
IFS, Director of Corporate & Executive Communications
Email: adam.gillbe@ifs.com

NORTH AMERICA / LATAM: Mairi Morgan
IFS, Director of Corporate & Executive Communications
Email: mairi.morgan@ifs.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

• NMPA grants Syntellix product approval for the world’s most important future market with more than 1.4 billion people
• Syntellix’ product approval for China is the largest and most important success in the company’s history; product approval in China was the company’s most important strategic and operational goal
• Syntellix had previously already been granted the accelerated ‘innovative pathway’ by the NMPA due to the exceptional benefits of its products
• In total, product approvals for Syntellix products have accumulated to date in countries with more than 5.5 billion inhabitants; product approvals had already been achieved in 73 countries and regions on five continents before current success in China
• Development of the prioritized core markets of China, India, and ASEAN is being carried out via Syntellix Asia Pte Ltd in Singapore as manufacturing facility & sales hub
• Syntellix Asia Pte Ltd has been supported by the Singapore Economic Development Board (EDB); Syntellix AG targets IPO on the Singapore Exchange (SGX)
• Syntellix and Syntellix Asia CEO Claassen: “After 7 years of focusing on China, we have achieved what almost everyone considered impossible. As a startup with its operational heart in Singapore, we have written a pioneering story worldwide, whose global medical success can now no longer be stopped. I sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in Asia by providing expertise and financial support for the establishment and expansion of our production facility in Singapore, which will now also become an Asia-wide and global sales hub as planned.”

HANOVER, Germany, and BEIJING and SINGAPORE, July 23, 2025 /PRNewswire/ — Syntellix AG, parent company of Singapore-based, Syntellix Asia Pte Ltd, has received product approval for the People’s Republic of China from the Chinese NMPA (National Medical Products Administration) in Beijing, which is responsible for the government regulation, registration, and monitoring of medical devices for the Chinese market. This product approval for the world’s most important future market, with more than 1.4 billion people, is by far the greatest and most important success in the company’s history. Syntellix AG had declared the development of the vast Chinese market its top strategic priority following Professor Dr Utz Claassen’s assumption of office as CEO of the company. After Syntellix had already previously been granted the accelerated ‘innovative pathway’ by the NMPA due to the particular advantages of its products, the initial approval process has now been completed extremely successfully. It was the most complex, intensive, and sophisticated approval process Syntellix has ever undergone in terms of product safety and quality management systems.

Syntellix now has obtained product approvals in countries with more than 5.5 billion inhabitants, or more than two thirds of the world’s population. Syntellix had previously received product approvals in 73 countries and regions on five continents, including all of Europe, Australia and New Zealand, South Africa, Singapore, Israel, and Saudi Arabia, as well as fast-growing, demographically dynamic countries such as Indonesia, Vietnam, the Philippines, and Thailand, as well as the world’s most populous country – India. China and India, with a combined population of almost 3 billion, open up entirely new dimensions of potential for the company in many respects. Syntellix’ highly innovative bioabsorbable metallic implants are produced by Syntellix Asia Pte Ltd which is based in JTC’s Tuas Biomedical Park. The Economic Development Board (EDB) had provided initial grants to Syntellix to support the establishment of its manufacturing presence and global sales hub in Singapore.

With the product approval now achieved in China, labelled by German news platform ‘Pressefeuer’ a ‘strategic triumph’ that could revolutionize the world of biomedical engineering and is a decisive step for the Hanover-based company’, Syntellix has achieved its most important strategic and operational goal. The strategic decision to develop the prioritized core markets of China, India, and ASEAN through Syntellix Asia Pte Ltd in Singapore, and to locate and expand the main production site in the ultra-modern and highly efficient island nation of Singapore, has proven to be both expedient and entirely correct. Establishing an Asia-centric production chain was strategically and operationally the right decision, as the production and sales hub in Singapore can supply and serve most of the world better and faster than from Germany or Europe. More than 3.5 billion people live in China, India, and the ASEAN region alone, which is more than 40 times the population of the Federal Republic of Germany, while at the same time experiencing significantly greater dynamics in terms of population growth, market growth, and economic power and perspectives.

For this purpose – establishing and expanding production in Singapore, tapping into the South Asian, Southeast Asian, and East Asian markets, and obtaining the necessary product approvals, particularly in China, – Syntellix, CEO Professor, Dr Utz Claassen, who is also Executive Chairman & CEO of Syntellix Asia Pte Ltd in Singapore, relocated his residence from Germany to Singapore more than five years ago in consultation and coordination with the Supervisory Board of Syntellix AG.

Syntellix CEO Professor Utz Claassen thus commented very positively on the product approval now achieved in China: “After more than 17 years of work and more than 7 years of focusing on China alone, we have achieved what almost everyone considered impossible. As a startup from Hanover with ist operational heart in Singapore, we have written a pioneering story worldwide, whose global medical success is now unstoppable. Those who win in China are strategically and operationally ideally positioned. The largest hospitals in China individually have higher patient volumes and more operations for our highly innovative products than most countries in the European Union. Without neglecting our homeland, we are proud and grateful to now be able to use our products, which are so beneficial for patients, users, and the healthcare system, in China, with its 5,000 years of cultural history, its magnificent medical tradition, and its unique future prospects. This is a game changer for our company, both qualitatively and quantitatively.”

Claassen emphasizes both the abstract and concrete positive conditions for the successful development of Syntellix’ activities in Asia, and also specifically in Singapore, and he is grateful for the very positive environment here: “I would like to expressly thank our outstanding Chinese partners for their tremendous support and cooperation, and the NMPA for an outstandingly differentiated and structured approval process. I would also like to sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in Asia by providing expertise and financial support for the establishment and expansion of our production facility in Singapore, which will now also become an Asia-wide and global sales hub as planned. This will create many attractive jobs in Singapore and set new international standards in biomedical engineering under market conditions that are not found in Germany or Europe, and building on government funding from the Republic of Singapore.”

Syntellix AG, as a joint-stock company under German stockholding law already a public company, also targets an IPO on the Singapore Exchange (SGX), the preparations of which have already been ongoing for several years with the help of Singaporean banks and law firms, well supported by SGX management under the leadership of its CEO Mr Loh Boon Chye and coordinated by Ms Alice Gwee.

About Syntellix:

Syntellix AG, a global pioneer in biomedical engineering, materials, and life sciences, is the only company in the world with approvals for bioabsorbable metallic implants in more than 70 countries on five continents, tens of thousands of successful surgeries, and the highest level of patient satisfaction. Syntellix is a global protagonist and market and technology leader in the field of bioabsorbable metallic orthopaedic implants. The company has received numerous prestigious awards and prizes, including the Innovation Award of the German Economy, the German Healthcare Industry Future Award, the German Medical Award, the STEP Award, the “Innovator of the Year” award, the German Innovation Award in Gold, and the Sustainability Award as “Product of the Year.” More than 50 medical and scientific publications have meanwhile documented the safety, efficacy, and reliability of the MAGNEZIX® implants developed by Syntellix, which have been described as “advantageous” and even “clinically superior” to conventional titanium implants for numerous clinical applications.

Syntellix Asia Pte Ltd in Singapore is a wholly-owned subsidiary of Syntellix AG. It is the operational heart of the group. The manufacturing facility for the highly innovative MAGNEZIX® implants is located in Singapore, in JTC’s Biomedical Park in Tuas. Syntellix Asia Pte Ltd, which in turn has the subsidiaries Syntellix China Pte Ltd, Syntellix Philippines Incorporated in San Juan City, and Syntellix India Private Limited in New Delhi and Jaipur, Rajasthan, serves not only the internationally leading medical hub of Singapore itself with its numerous world-class hospitals, but also major markets in countries throughout the ASEAN region, including Thailand, Malaysia, Vietnam, and Indonesia.”

Contact:
T +49 511 270 413 50
F +49 511 270 413 79
info@syntellix.com
www.syntellix.com